Vaxart Inc. (VXRT) Company Gross Revenue

Symbol and logo of brand Vaxart (VXRT)

Vaxart, Inc. (VXRT) does not pay dividends due to capital requirements and clinical trial risks. The company's trading revenue dynamics serve as an indicator of market confidence, where the value of 0.05 expresses the metric level. Vaxart, Inc. (VXRT) is developing the VAAST platform to combat influenza by creating affordable tablet vaccines. Eliminating syringes and cold chain requirements radically reduces logistics costs, providing powerful operating leverage.

VXRT - Vaxart Corp Revenue and Sales Volume over the range 07/04/2022 - 07/19/2025

Comprehensive metric breakdowns and analytics for Vaxart Corp (VXRT)

- price and consensus price forecast:
Comprehensive company analysis:Vaxart Corp - VXRT
Product sample of Vaxart Inc.

This indicator aggregates total cash inflows from product sales, reflecting market demand dynamics and the pace of commercial expansion through revenue calculations. The current value of 0.05 confirms that Vaxart, Inc. (VXRT) is currently at an R&D plateau, where the absence of a commercial product renders the company's sales volume static, highlighting the business's dependence on external financing and grants.